Fig. Megaloblastic anemia showing megaloblastics cells |
An increased MCV can be due to a number of reasons but
careful review of the patient's history and blood smear can narrow the
diagnostic possibilities. The
differential can be divided into two broad categories based on RBC morphology.
Round
macrocytosis-due to abnormal lipid composition of the erythrocyte
membrane. Common etiologies include:
1. Alcoholism.
2. Liver Disease.
3. Renal Disease.
4. Hypothyroidism ("myxedema of
the red cell").
1. Drug effect including cytotoxic chemotherapy.
2. Megaloblastic Anemias-Folate Deficiency or Vitamin
B12 deficiency - Patients will have hypersegmented neutrophils on
review of the peripheral smear.
3. Myelodysplasia
- Patients often have hyposegmented neutrophils and abnormal platelet
morphology.
Patients with increased reticulocyte counts can also
have an increase MCV due to the large size of the reticulocyte (MCV = 160).
ABSORPTION AND METABOLISM OF VITAMIN B12 AND
FOLATE
Folate: The body
stores very little folate (several weeks) and maintenance of folate stores is
dependent on adequate dietary intake.
Folate is found in green leafy vegetables, and liver. Folate is absorbed in the small bowel and
circulates in a free form or loosely bond to albumin.
Vitamin B12: In
contrast to folate the body stores copious amounts of vitamin B12
(2-6 years). This is fortunate as the
absorption of vitamin B12 is complex and can be interrupted by a
variety of mechanisms. Vitamin B12
is synthesized by microbes and the major dietary source is animal protein. When animal protein is ingested, vitamin B12
is freed from the protein and binds to "R proteins". The R protein-vitamin B12 complex
travels to the duodenum where pancreatic enzymes destroy the R protein. This allows intrinsic factor (IF) to bind to
vitamin B12. This IF-vitamin
B12 complex is absorbed only in the last 1-2 feet of terminal
ileum. Vitamin B12 binds to
transcobalamin II and is delivered to tissues.
Fig. Vitamin B12 and folate metabolic pathway |
VITAMIN B12 AND FOLATE- METABOLIC PATHWAYS
Both vitamin B12 and folate are key
components in the synthesis of DNA due to their role in conversion of uridine
to thymidine. When
methyltetrahydrofolate loses a methyl group to form tetrahyrodrofolate, vitamin
B12 "shuttles" the methyl group to homocysteine converting
it to methionine. Tetrahydrofolate is
eventually converted to methylenetetrahydrofolate which is required for
thymidine synthase. Vitamin B12 other role is a co-factor in the
conversion of methymalonyl-CoA to succinyl-CoA.
CONSEQUENCES OF VITAMIN B12 OR FOLATE
DEFICIENCY
When vitamin B12 or folate is deficient,
thymidine synthase function is impaired and DNA synthesis is interrupted. As described above this leads to
megaloblastic changes in all rapidly dividing cells. The inability to synthesized DNA leads to
ineffectual erythropoiesis. There is
often erythroid hyperplasia in the marrow but most of these immature cells die
before reaching maturity. This process, intramedullary
hemolysis, leads to the classic biochemical picture of hemolysis-elevated
LDH and indirect bilirubinemia. The LDH
level is often in the 1,000's in patients with megaloblastic anemia. The lack of DNA synthesis affects the
neutrophils leading to nuclear hypersegmentation. The anemia is of gradual onset and is often
very well tolerated despite low hematocrits.
Often a mild pancytopenia is seen but thrombocytopenia can be severe.
Other rapidly dividing tissue are influenced by the
megaloblastic process. In the GI tract
this can lead to atrophy of the luminal lining and further malabsorption. This also leads to the classic sign of tongue
smoothing.
As discussed further below, only vitamin B12
deficiency leads to neurological damage.
The mechanism is unknown.
ETIOLOGIES OF FOLATE DEFICIENCY
Decreased intake- The
average intake of folate in the diet is only 2-300 ug/day which is less than
the estimated daily requirement. Thus,
for most people a poor diet or decrease eating will lead to folate deficiency.
Increased requirements-Patients
who are pregnant, have hemolytic anemia, or psoriasis have increased needs for
folate which can cause them to rapidly develop folate deficiency if intake is
not kept up.
Malabsorption
Drugs - Patient
with underlying mild folate deficiency are more susceptible to
trimethoprim/sulfa,
pyrimethamine and methotrexate toxicity. Oral contraceptive and anticonvulsants lead
to increase consumption of folate.
Alcohol- Alcohol
affects several aspects of folate metabolism.
Alcoholics have poor intake of folate.
In addition, folate metabolism is interfered with leading to a
functional folate deficiency. Alcoholics
have an inability to mobilize folate stores and can have depleted tissue stores
with normal serum levels of folate.
ETIOLOGIES OF VITAMIN B12 DEFICIENCY
Inadequate intake is rare
but seen in very strict vegins.
Abnormal gastric events include
being unable to dissociated vitamin B12 from food due to lack of
stomach acid or enzymes. This is a
recently recognized group of patients which may compose a very large subset of
patients with vitamin B12 deficiency. 10-30% percent of patients with partial
gastrectomy will develop vitamin B12 deficiency.
Deficient intrinsic factor most
commonly occurs due to destruction of parietal cells by autoantibodies
(pernicious anemia).
Abnormal small bowel events include
pancreatic insufficiency, blind loops syndromes (bacterial absorbing vitamin B12-IF
complexes) and patients infested with Diphyllobothrium latum.
Abnormal mucosal events including
malabsorption syndromes and surgical removal of the terminal ileum.
Drugs - Metformin, PPIs
APPROACH TO THE PATIENT WITH A MEGALOBLASTIC ANEMIA
1. Recognizing that a megaloblastic
anemia is present.
2. Diagnosing vitamin B12
and or folate deficiency
3. Determining the underlying cause.
4. Therapy
DIAGNOSING VITAMIN B12 AND OR FOLATE
DEFICIENCY
It turns out that simply measuring serum levels of B12
or folate is very inadequate to diagnosis deficiency. Up to 30% of people with low normal B12
levels will be deficient and many people with low B12 stores have
normal tissue stores. A more reliable
method is to assay for the metabolic products that accumulate in B12
deficiency. Since B12 is
involved in conversion of homocysteine to methionine, lack of B12
will lead to elevated homocysteine level.
Also B12 is involved in conversion of methylmalonic acid to
succinyl so in B12 deficiency, methylmalonic acid accumulates. Both homocysteine and methylmalonic acid
assays are widely available and should be the first line tests for B12
deficiency.
Serum folate levels are also very unreliable. Since folate is needed for conversion of
homocysteine to methionine, serum homocysteine will also accumulate in folate
deficiency and is a more sensitive marker of tissue folate stores.
DEFICIENCY
|
HOMOCYSTEINE
|
METHYLMALONIC
ACID
|
FOLATE
|
ELEVATED
|
NORMAL
|
B12
|
ELEVATED
|
ELEVATED
|
Increased
Homocysteine level:
B12
or folate deficiency, renal failure (kidney significant organ for homocysteine
metabolism).
Implications:
1)
Marker for possible nutritional
deficiency
2)
Elevated levels of homocysteine are associated with an increased risk of
atherosclerosis or venous thrombosis.
Increased
Methylmalonic Acid
Causes:
B12
deficiency, renal failure (MMA renal excreted), methylmalonic aciduria (rare)
Implications:
B12
deficiency.
DETERMINING
THE UNDERLYING CAUSE
In
the majority of patients with folate deficiency, one can determine the
underlying cause by history. The key
concern in vitamin B12 deficiency is determining a which point in
the complex pathway of vitamin B12 absorption the "lesion"
is. The Schilling test is a test of
vitamin B12 absorption.
Patients are given radiolabeled vitamin B12 orally and a
large dose of vitamin B12 is given intravenously. The IV dose of vitamin B12
prevents binding any absorbed labeled vitamin B12 and this is
excreted. The amount of excreted vitamin
B12 is reflective of vitamin B12 absorption. The Schilling test is NOT a test of vitamin B12 deficiency but a tool to
determine the etiology of the deficiency.
The tradition Schilling test is call "stage I". If less than 8% of the labeled vitamin B12
is excreted then one can perform the Schilling test with a variety of
diagnostic maneuvers to pinpoint the lesion.
This includes giving intrinsic factor, pancreatic enzymes, or
antibiotics.
The
Schilling test has several shortcomings.
One is it require patient cooperation in collecting the 24 hour urine
sample. As noted above patients can have
secondary malabsorption due to vitamin B12 deficiency. The classic Schilling test will not detect
abnormalities in patients with difficulties in disassociating vitamin B12
from food.
Patients
with pernicious anemia can be detected by assaying for autoantibodies but these
tests can lack diagnostic specificity.
Antibodies to IF are specific but not sensitive and antibodies to
parietal cells are sensitive but not specific for pernicious anemia.
THERAPY
Patients
with severe megaloblastic anemia need immediate therapy. One should quickly obtain serum vitamin B12
and red cell folate levels and then give 1-5 mg of folate and 1000 ug IM of
vitamin B12. Patients should
be treated daily with folate. Schedules
for vitamin B12 replacement vary but a common approach to all is
daily therapy for one week to rapidly build up stores and supply vitamin B12
to tissues, then weekly for a month, then monthly life-long. Patients with severe anemia should have
increased reticulocyte by day three and increased hematocrit by day 5. Patients with alcoholism and folate
deficiency can take up to three weeks to respond to folate therapy. It used routine to use IM injection to
replace vitamin B12. Oral
therapy with 1-2000 ug/day has been tested and has been found to be just as
reliable as IM therapy and is becoming more widely used.
Although
patients will megaloblastic anemia often present with severe anemia,
transfusion therapy is rarely indicated.
Since the anemia is rapidly reversible with therapy there is little
justification for exposing the patient to the risk of transfusion except if the
patient is having life-threatening symptoms such as severe ischemia. A further hazard of transfusion is since some
of these patients have high-output heart failure, overzealous transfusion may
lead to pulmonary edema.
VITAMIN B12-
NEUROLOGICAL CONSEQUENCES
Recently
it has become clear the patients can have neurological damage due to vitamin B12
deficiency without anemia. In fact as
many as 30% of patients with neurological disease due to vitamin B12
deficiency will have no or only subtle hematological symptoms. Patients with the most severe neurological
manifestation often have mild hematological disease. Thus it is appearing that vitamin B12
deficiency may exhibit two different types of disease states in humans -
hematological or neurological.
Neurological symptoms are reversible if found early but those present
for over a year slowly, if ever, improve.
The
neurological symptoms include:
o
Paresthesias-most
often in fingers and toes. The most
common symptom of vitamin B12 deficiency.
o
Diminished
vibratory sense
o
Gait
ataxia
o
Increases
deep tendon reflexes
o
Memory
loss
o
Personality
change
o
Orthostatic
hypotension
VITAMIN B12 AND THE ELDERLY
On
routine screening as many as 10-23% of elderly patients will have low vitamin B12
levels. One study found that 14.5% had
levels below 300 pg/ml with 56% of these patients having increased levels of
homocysteine and methylmalonic acid indicative of tissue vitamin B12
deficiency. The most common mechanism is
inability to absorb vitamin B12 from food. It is speculated the rapid rise in the use of
H2 blockers will increase this problem in this patient population.
Patients with dementia have lower levels of vitamin B12 then those
without but treatment with vitamin B12 is often not effective,
perhaps due to the long duration of the neurological damage. Studies are underway to examine the
relationship of vitamin B12 deficiency to neurological disease in
the elderly and the effects of early intervention.
CLINICAL
DIFFERENCES BETWEEN VITAMIN B12 AND FOLATE DEFICIENCIES
Folate
Deficiency
|
Vitamin
B12
Deficiency
|
|
Most
common cause
|
Dietary
deficiency
|
Malabsorption
|
Time
to development
|
Months
|
Years
|
Neurologic abnormalities
|
No
|
Yes
|
Response to treatment with
vitamin B12
|
No
|
Yes
|
Response
to treatment with folate
|
Yes
|
Hematologic
- Yes
Neurologic
- No
|
Source:
Thomas G. DeLoughery, MD FACP
Professor of Medicine, Pathology,
and Pediatrics
Oregon Health Sciences University
Portland, Oregon
No comments:
Post a Comment